CClinicalTrials.gg
TerminatedNCT01341444PIMSUpdated Oct 16, 2024Results posted

The Use of the Prevena Incision Management System (PIMS) on Closed Incisions in Renal Transplant Subjects

An interventional study of Prevena Incision Management System and Standard of Care for Surgical Incisions in Surgical Site Reaction, sponsored by KCI USA, Inc. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by KCI USA, Inc · Not applicable, Interventional, and Treatment

Why this study was terminated
Enrollment Difficulties
Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is being conducted to see how safe and effective the Prevena Incision Management System "Prevena" is when placed over a renal transplantation incision. Prevena provides negative pressure (suction) wound therapy. Prevena will be tested while applied during the time each subject is hospitalized and up to 5 days after the surgery. Prevena is a small portable negative pressure device which consists of a therapy unit that delivers negative pressure. It also includes a dressing system that is intended for use over closed incisions after surgery.

The intent of this study is to evaluate Prevena versus the standard care that a doctor would use normally after a kidney transplant.

Read the detailed description

This is a randomized, single-center, comparative interventional study looking at the effect of Prevena™ on renal transplant surgical Subjects compared to a control arm treated with the standard-of-care wound dressing. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of PrevenaTM in this clinical indication.

02

Conditions studied

  • Surgical Site Reaction

Browse trials for

03

In context

Surgical Wound

519 studies on the registry are indexed under Surgical Wound; 71 are open to participants now.

This study's enrollment of 63 is below the median of 80 across 412 interventional studies indexed under Surgical Wound.

Browse Surgical Wound studies →

Lead sponsor

KCI USA, Inc is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Pre-operative Inclusion Criteria

The Subject:

  1. is an adult ≥ 18 years old of either gender
  2. is able to provide their own informed consent Protocol: AHS.2012.Prevena.Cooper.01 v 4.0 Confidential/Property of KCI USA, Inc. Page 6 of 71
  3. will undergo open renal transplant surgery within the next 30 days
  4. will require a surgical incision able to be covered completely by the PIMS dressing
  5. is pre-operatively assessed to undergo a procedure with a CDC Wound Classification of:

    1. Class I (Clean): An uninfected operative wound in which no inflammation is encountered and the respiratory, alimentary, genital, or uninfected urinary tract is not entered

      • OR -
    2. Class II (Clean Contaminated): An operative wound in which the respiratory, alimentary, genital, or uninfected urinary tract are entered under controlled conditions and without unusual contamination
  6. is willing and able to return for all scheduled and required study visits
  7. if female, must test negative on serum pregnancy test
  8. if a female of child-bearing potential, must be willing to utilize an acceptable method of birth control (e.g., birth control pills, condom with spermicide, diaphragm with spermicide, implants, IUD, injections, vaginal rings, hormonal skin patch, etc.) for the duration of study participation
  9. is not concurrently enrolled in a clinical trial which may impact subject health or the surgical incision site

Intra-operative Inclusion Criteria Subjects must meet the following intra-operative inclusion criteria to be eligible for randomization.

The Subject:

  1. continues to meet all pre-operative inclusion criteria
  2. has undergone a Class I or II CDC Wound Classification procedure resulting in a closed surgical incision able to be covered completely by the PIMS dressing

Pre-operative Exclusion Criteria

The Subject:

  1. has a BMI \< 18.5 kg/m2 and > 40 kg/m2
  2. has a systemic infection at the time of open renal transplant surgery
  3. has a remote-site skin infection at the time of open renal transplant surgery
  4. is preoperatively assessed to undergo a procedure with a CDC Wound Classification of:

    1. Class III (Contaminated): Open, fresh, accidental wounds, and/or major breaks in sterile technique or gross spillage from the gastrointestinal tract

      • OR -
    2. Class IV (Dirty-Infected): Old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera
  5. has a known allergy or hypersensitivity to silver, or drape materials that contain acrylic adhesives

Intra-Operative Exclusion Criteria Subjects who meet any of the following intra-operative exclusion criteria are considered screen failures and are not eligible for randomization.

The Subject:

  1. is found to meet any of the pre-operative exclusion criteria
  2. has obvious contamination of the surgical incision
  3. requires external surgical drains that will be covered by the PIMS dressing
  4. is determined to have a CDC Wound Classification of:

    1. Class III (Contaminated): Open, fresh, accidental wounds, and/or major breaks in sterile technique or gross spillage from the gastrointestinal tract

      • OR -
    2. Class IV (Dirty-Infected): Old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera Protocol: AHS.2012.Prevena.Cooper.01 v 4.0 Confidential/Property of KCI USA, Inc. Page 8 of 71
  5. requires a transfusion, has disseminated-intravascular coagulopathy (DIC) or other medical or surgical conditions during open renal transplant surgery deemed by the Investigator to pose a prohibitively high risk for surgical re-exploration
  6. is deemed unable to continue in the study by the Investigator as the Subject's safety or well-being may be jeopardized.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Prevena Incision Management System

    Negative Pressure Therapy Device

    Device: Prevena Incision Management System

  • Placebo comparator
    Standard of Care for Surgical Incisions

    Sterile gauze and a non-penetrable barrier

    Other: Standard of Care for Surgical Incisions

Interventions

  • DevicePrevena Incision Management System

    It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).

  • OtherStandard of Care for Surgical Incisions

    Sterile 4X4 Non-Penetrable barrier

06

What researchers measure

Primary outcomes

  1. Number of Participants With Surgical Site Complications (SSCs)

    The primary objective to compare short-term surgical incision-related clinical outcomes in Subjects undergoing open renal transplant surgery when treated with Prevena vs. the standard-of-care wound dressing. Clinical outcomes of interest are defined as Surgical Site Complications (SSCs) that include incisional fluid accumulation (i.e. seroma, hematoma, abscess), dehiscence, surgical site infection (SSI). These outcomes will be compared to a control group consisting of subjects screened for the same inclusion/exclusion criteria but treated with standard-of-care incision dressing.

    Time frame: 62 Days

07

Results

Posted Jul 2, 2017

Participant flow

Participant flow — Overall Study
MilestonePrevena Incision Management SystemStandard of Care for Surgical Incisions
Started3132
Completed2629
Not completed53

Outcome measures

PrimaryNumber of Participants With Surgical Site Complications (SSCs)

The primary objective to compare short-term surgical incision-related clinical outcomes in Subjects undergoing open renal transplant surgery when treated with Prevena vs. the standard-of-care wound dressing. Clinical outcomes of interest are defined as Surgical Site Complications (SSCs) that include incisional fluid accumulation (i.e. seroma, hematoma, abscess), dehiscence, surgical site infection (SSI). These outcomes will be compared to a control group consisting of subjects screened for the same inclusion/exclusion criteria but treated with standard-of-care incision dressing.

Time frame:
62 Days
Reported as:
Count of participants · Participants
Number of Participants With Surgical Site Complications (SSCs)
ParticipantsPrevena Incision Management SystemStandard of Care for Surgical Incisions
Number of Participants With Surgical Site Complications (SSCs)68

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prevena Incision Management System—11/31 (35.5%)0/31 (0%)
Standard of Care for Surgical Incisions—13/32 (40.6%)0/32 (0%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPrevena Incision Management SystemStandard of Care for Surgical Incisions
HypercreatininaemiaMetabolism and nutrition disorders1/313/32
Kidney Transplant RejectionImmune system disorders2/310/32
HaematomaVascular disorders2/311/32
Wound DehiscenceInjury, poisoning and procedural complications0/312/32
Myocardial InfarctionCardiac disorders1/310/32
Ankle FractureInjury, poisoning and procedural complications1/310/32
Complications of Transplanted KidneyInjury, poisoning and procedural complications1/310/32
Post Procedural HaemorrhageInjury, poisoning and procedural complications1/311/32
Blood Creatine IncreasedInvestigations1/311/32
Urine Output DecreasedInvestigations1/310/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)Prevena Incision Management SystemStandard of Care for Surgical IncisionsTotal
Mean48.71 ± 11.2951.75 ± 12.1950.25 ± 11.76
Sex: Female, Male
Sex: Female, Male(Participants)Prevena Incision Management SystemStandard of Care for Surgical IncisionsTotal
Female91322
Male221941
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Prevena Incision Management SystemStandard of Care for Surgical IncisionsTotal
Hispanic or Latino156
Not Hispanic or Latino302757
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Prevena Incision Management SystemStandard of Care for Surgical IncisionsTotal
American Indian or Alaska Native011
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American181432
White121527
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01341444
Lead sponsor
KCI USA, Inc
Responsible party
Sponsor
First posted
Apr 25, 2011
Start date
Aug 2013
Primary completion
May 2016
Completion
May 2016
Results posted
Jul 2, 2017
Last update
Oct 16, 2024

Study contacts

Matthew Cooper, MD
principal investigator · MedStar Georgetown University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion